OptiNose is pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat and allergy specialists. Co.'s first commercial product, XHANCE® (fluticasone propionate) nasal spray, 93 microgram, is a therapeutic utilizing its proprietary Optinose Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and, if approved, chronic rhinosinusitis without nasal polyps (chronic sinusitis). Co.'s other product candidate includes OPN-019, which combines its liquid EDS device with an antiseptic. The OPTN stock yearly return is shown above.
The yearly return on the OPTN stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2019 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the OPTN annual return calculation with any dividends reinvested as applicable (on ex-dates).
|